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Abstract
Background: The role of advanced glycation end products (AGEs) in the development of diabetes, especially
diabetic complications, has been emphasized in many reports. Accumulation of AGEs in the vasculature triggers a
series of morphological and functional changes in endothelial cells (ECs) and induces an increase of endothelial
permeability. This study was to investigate the involvement of RhoA/ROCK-dependent moesin phosphorylation in
endothelial abnormalities induced by AGEs.
Methods: Using human dermal microvascular endothelial cells (HMVECs), the effects of human serum albumin
modified-AGEs (AGE-HSA) on the endothelium were assessed by measuring monolayer permeability and staining of
F-actin in HMVECs. Activations of RhoA and ROCK were determined by a luminescence-based assay and
immunoblotting. Transfection of recombinant adenovirus that was dominant negative for RhoA (RhoA N19) was
done to down-regulate RhoA expression, while adenovirus with constitutively activated RhoA (RhoA L63) was
transfected to cause overexpression of RhoA in HMVECs. H-1152 was employed to specifically block activation of
ROCK. Co-immunoprecipitation was used to further confirm the interaction of ROCK and its downstream target
moesin. To identify AGE/ROCK-induced phosphorylation site in moesin, two mutants pcDNA3/HA-moesinT
558A and
pcDNA3/HA-moesinT
558D were applied in endothelial cells.
Results: The results showed that AGE-HSA increased the permeability of HMVEC monolayer and triggered the
formation of F-actin-positive stress fibers. AGE-HSA enhanced RhoA activity as well as phosphorylation of ROCK in a
time- and dose-dependent manner. Down-regulation of RhoA expression with RhoA N19 transfection abolished
these AGE-induced changes, while transfection of RhoA L63 reproduced the AGE-evoked changes. H-1152
attenuated the AGE-induced alteration in monolayer permeability and cytoskeleton. The results also confirmed the
AGE-induced direct interaction of ROCK and moesin. Thr558 was further identified as the phosphorylating site of
moesin in AGE-evoked endothelial responses.
Conclusion: These results confirm the involvement of RhoA/ROCK pathway and subsequent moesin Thr558
phosphorylation in AGE-mediated endothelial dysfunction.
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Background
Advanced glycation end products (AGEs) are a hetero-
geneous group of complex compounds that are formed
irreversibly in serum and tissues via a chain of non-
enzymatic chemical reactions [1]. The role of AGEs in
the development of diabetes, especially diabetic compli-
cations, has been emphasized in many reports [2,3] and
the level of AGEs is correlated with the severity of dia-
betic complications [4-7]. Direct effects of AGEs include
formation of extracellular cross-links that may trap var-
ious unrelated macromolecules. Furthermore, AGEs can
bind to various receptors, such as the receptor for AGE
(RAGE) or AGE receptors 1-3 (AGER1-3), leading to
complex effects on cellular function via complicated
transduction pathways [8-10]. The major AGE receptor
(RAGE) enhances inflammation, while AGER1 promotes
the removal of AGEs and blocks inflammation [11]. The
vascular endothelium is the front-line organ for vascular
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dysfunction of the microvascular endothelial barrier
playing a critical role in the pathogenesis of insulin
resistance and diabetes [12]. Accumulation of AGEs in
the vasculature triggers a series of morphological and
functional changes in endothelial cells (ECs) and induces
an increase of endothelial permeability [13]. It has been
reported that AGEs cause significant disorganizations of
the F-actin cytoskeleton, disruption of tight junctions
and adherens junctions in cultured human umbilical
venous endothelial cells (HUVECs), and increase the
permeability of EC monolayers [14,15]. The Rho family
of small GTPase proteins control a wide variety of cellu-
lar processes. RhoA is one of the best-known members
of this family and the Rho kinases (ROCK) are the first
and the best-characterized RhoA effectors. By modulat-
ing the organization of the actin cytoskeleton, RhoA/
ROCK signaling regulates a wide range of cellular func-
tions, such as contraction, motility, proliferation, and
apoptosis. It has been shown that ROCK-dependent re-
arrangement of the actin cytoskeleton and changes of
cell contractility are involved in the regulation of
endothelial permeability [16-19]. Our previous studies
have also suggested the involvement of ROCK in AGE-
induced endothelial responses. Inhibition of ROCK with
Y-27632 was reported to reduce the AGE-evoked forma-
tion of actin stress fibers and the weakening of adherens
junction [15] in HUVECs. Y-27632 also abolished the
AGE-induced increase of ROCK phosphorylation [20].
Using anti-RAGE antibody, we and Hirose et al. have
demonstrated in HMVECs and HUVECs, respectively,
that activation of RhoA depends on the binding of
AGEs to RAGE [14,20].
Since ROCK does not directly act on F-actin and
other cytoskeletal molecules, there is a missing link
between the activation of ROCK and the cytoskeleton
reorganization. ERM (ezrin/radixin/moesin) proteins are
emerging as the potential candidates that likely mediate
this process. Serving as cross-linkers between actin fila-
ments and plasma membrane, ERM molecules are
engaged in cell adhesion, microvilli formation, cell moti-
lity, etc [21-23]. Moesin is regarded as the most impor-
tant ERM in endothelia since it is the dominant ERM
expressed in endothelial cells [8,24]. It has been demon-
strated by several experiments that Rho-ROCK is a typi-
cal upstream pathway for the phosphorylation of moesin
[23]. On the basis of in vitro and in vivo studies [20,25],
Rho kinase is also postulated to phosphorylate moesin
in AGE-induced endothelial response, but there is still a
lack of direct evidence for the interaction of ROCK and
moesin in AGE-evoked endothelial alteration.
One of the purposes of this study was to further
investigate the specific effect of RhoA/ROCK pathway
on endothelial responses to AGEs. By transfection of
recombinant adenoviruses targeting RhoA activity and
usage of a more specific ROCK inhibitor, we explored
the contribution of this signaling pathway to the AGE-
induced increase of endothelial monolayer permeability
and alterations of the F-actin cytoskeleton by clarifying
the phosphorylation state of RhoA and ROCK after
exposure to AGEs. This present study is also aimed to
further confirm the interaction of ROCK and its down-
stream target moesin by using Co-immunoprecipitation
(Co-IP). To identify the AGE/ROCK-induced phosphor-
ylation site in moesin, two mutants pcDNA3/HA-moe-
sinT
558A and pcDNA3/HA-moesinT
558D were applied in
endothelial cells and the AGE-stimulated responses
were compared.
Materials and methods
Chemicals and reagents
AG - L I S A ™ RhoA activation assay kit was purchased
from Cytoskeleton (Denver, USA). Antibody recognizing
total ROCK, ROCK inhibitor H-1152, and protein G
plus/protein A agarose suspension were obtained from
Calbiochem (USA), while antibody recognizing p-ROCK
came from Upstate (NY, USA). RhoA N19 recombinant
adenovirus (dominant negative) and RhoA L63 recombi-
nant adenovirus (constitutively active) were purchased
from Cell Biolabs (San Diego, CA, USA). Antibody
recognizing moesin was purchased from Abcam
(Abcam, UK) while anti-phosphorylated (p-)moesin
(Thr558) antibody was purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Antibody recognizing HA
was purchased from Cell Signaling Technology (CST,
USA). Lipofectamine™ LTX and PLUS™ reagents were
obtained from Invitrogen Technology. Primers were
designed using Primer Premier 5 software and synthe-
sized by Invitrogen (USA). Restriction enzymes EcoR I
and Xho I were from Takara (Japan). High Fidelity DNA
polymerase KOD-Plus, KOD-Plus-Mutagenesis kit and
Thunderbird SYBR qPCR Mix were obtained from
Toyobo (Japan). Rhodamine-phalloidin was obtained
from Molecular Probe (Carlsbad, CA, USA). MCDB 191
medium, DMEM medium, fetal bovine serum (FBS),
trypsin, glutamine, penicillin, and streptomycin were all
from Gibco BRL (Grand Island, NY, USA). Chemicals
were purchased from Sigma (St. Louis, MO, USA)
unless otherwise indicated.
Preparation of AGE-HSA
Advanced glycation end product-modified human serum
albumin (AGE-HSA) was prepared as previously
reported [20], essentially according to the protocol of
Hou et al [26,27]. Briefly, human serum albumin (150
mmol/L, pH 7.4) was incubated in PBS with D-glucose
(250 mmol/L) at 37°C for 8 weeks, while control albu-
min was incubated without glucose. After the incubation
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PBS and purified. The endotoxin content was measured
with a limulus amebocyte lysate assay (Sigma, St. Louis,
MO, USA) and was found to be less than 500 U/L in
both solutions. AGE-specific fluorescence was deter-
mined by ratio spectrofluorometry, showing that AGE-
HSA had an AGE content of 74.802 U/mg protein,
while native albumin had an AGE content of less than
0.9 U/mg protein.
Cells and culture conditions
A human dermal microvascular endothelial cell
(HMVEC) line was purchased from Cell Applications
(San Diego, CA) [28]. Cells were grown in 100-mm
dishes or 6-well plates and were maintained in MCDB
131 containing endothelial cell growth supplements,
20% FBS, and 2 mmol/L L-glutamine at 37°C in a humi-
dified atmosphere with 5% CO2. Primary human umbili-
cal endothelial cells (HUVECs) (from Sciencell) were
maintained in DMEM containing 10% FBS at 37°C in a
humidified atmosphere with 5% CO2.
Stimulations of HMVECs
In all experiments, HMVECs were grown to 90% conflu-
ence and starved of serum for 2 hours before being sti-
mulated with AGE-HSA at the indicated doses and for
the indicated times. The AGE-HSA concentrations used
in this experiment were based on data from our previous
studies of HMVECs or freshly cultured primary HUVECs
[15,20]. To clarify the involvement of RhoA in AGE-
induced endothelial responses, HMVECs were infected
with RhoA N19 recombinant adenovirus (dominant
negative) according to the manufacturer’s instructions at
24 h before stimulation with AGE-HSA. As the positive
control, HMVECs were infected with RhoA L63 recombi-
nant adenovirus (constitutively active) for 24 h before
being studied. For inhibitor treatment, HMVECs were
pretreated with H-1152 (20 μmol/L) and then cultured in
fresh complete medium with 50 mg/L AGE-HSA for 8 h.
Measurement of RhoA activity
RhoA activity was determined by using a luminescence-
based G-LISA™ RhoA activation assay kit (Kit #BK121,
Cytoskeleton, Inc., Denver, CO) according to the manu-
facturer’s instructions. This assay employs a Rho-GTP-
binding protein coating the wells of a 96-well plate.
Active, GTP-bound Rho in cell lysates binds to the
wells, while inactive GDP-bound Rho is removed
through the washing steps. Then the bound active RhoA
is detected by incubation with a specific RhoA antibody
followed by an HRP-conjugated secondary antibody and
a detection reagent, after which the luminescence is
read on a microplate luminescence reader (MDC Spec-
traMax M5, USA). HMVECs were cultured in 6-well
plates and treated as indicated above. Proteins were har-
vested by incubating the provided cell lysis buffer with
protease inhibitors, and centrifugating at 14,000 rpm at
4°C for 2 min to remove cell debris. The protein con-
centration was determined according to the manufac-
turer’s protocol, and cell extracts were equalized to a
protein concentration of 1.5 mg/ml for assay. Lumines-
cence was detected according to the manufacturer’s
recommendations with minor modifications after incu-
bation overnight at 4°C with the primary anti-RhoA
antibody.
ROCK and moesin phosphorylation and immunoblotting
Total cellular extracts were prepared by lysis and sonica-
tion of the cells in lysis buffer (20 mmol/L Tris pH 7.4,
2.5 mmol/L EDTA, 1% Triton X-100, 1% deoxycholic
acid, 0.1% SDS, 100 mmol/L NaCl, 10 mmol/L NaF, 1
mmol/L Na3VO4) with protease and phosphatase inhibi-
tors. Samples were subjected to SDS-PAGE, and proteins
were transferred to polyvinylidene fluoride (PVDF) mem-
branes. Blots were blocked with 5% bovine serum albu-
min in TBS containing 0.5% Tween 20 (TBS-T) for 1 h
and then incubated with an 1:1000 dilution of primary
antibody for p-ROCK (Upstate, NY, USA) or p-moesin
(Santa Cruz, CA) overnight at 4°C on a rocker. After
three washes for 5 min each with TBS-T, the blots were
incubated with an 1:1000 dilution of HRP-conjugated
species-specific respective secondary antibody for 1 h at
room temperature. After washing three times for 5 min
each with TBS-T, protein bands were visualized by che-
miluminescence and then densitometric analysis was
done by using Kodak IS2000R Imaging Station.
Plasmid Constructs and Site-specific Mutagenesis
The full-length cDNA of moesin was obtained from
HUVECs by RT-PCR and was ligated into eukaryotic
expression vector pcDNA3/HA to obtain recombinant
plasmid pcDNA3/HA-moesin, which was identified by
EcoR I/Xho I double digestion and nucleotide sequen-
cing. The point mutations of pcDNA3/HA-moesin were
generated by inverse PCR with a site-specific mutagen-
esis kit (Toyobo, Japan) [29,30]. The two mutants,
pcDNA3/HA-moesin
T558A and pcDNA3/HA-moe-
sin
T558D, were generated using primer A forward, 5’
GCCAAGCAGCGCATTGACGAATTTGAGTC 3’,a n d
reverse, 5’ GTTGCCCTGCCGGATCTGGCGC 3’,a n d
primer B forward, 5’GACAAGCAGCGCATTGAC-
GAATTTGAGTCTATG 3’, and reverse, 5’
GTTGCCCTGCCGGATCTGGCGC 3’, respectively.
The mutations were identified by nucleotide sequencing.
Transfection of plasmids to HUVECs
The transfection of plasmids was carried out by endo-
free plasmid midiprep kit. HUVECs of about 90%~95%
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tics were transfected with plasmids encoding HA-tagged
two mutant forms of moesin (T558A and T558D) using
Lipofectamine™ LTX and PLUS™ reagents (Invitrogen)
according to the manufacturer’s instructions. Briefly, for
a6 - w e l lf o r m a t ,1μg DNA was incubated in 500 μl
Opti-MEM (antibiotics-free) while 8 μl lipofectamine
LTX and 2 μl plus reagent were added and left at room
temperature for 30 min. The cultured cells were washed
once with Opti-MEM. The DNA-lipid complexes were
added to the plates and incubated for 24 h, followed by
stimulation with AGE-HSA (50 mg/L, 1 h). The cells
were then used for Realtime PCR, immunoblotting,
endothelial monolayer permeability assay, or immuno-
fluorescence, respectively.
Quantitative Realtime Reverse Transcription PCR
Total RNA was isolated from HUVECs by total RNA
extraction kit (Biomegia USA) according to the manu-
facturer’s protocol. Realtime PCR amplification was per-
formed with moesin-specific primers. Total RNA of 1
μg was used as templates for cDNA synthesis in the
reverse transcriptase reaction. After an initial 60 s pre-
denature and 15 s denaturation at 95°C, cDNA was
amplified for 40 cycles and then annealed at 60°C for 60
s for moesin and GAPDH. Under optimized conditions
there was a single melting curve and no primer-dimer
formation. The copy number for each mRNA was deter-
mined using a standard curve generated with external
standards of known copy number. All the primers were
designed using Primer Premier 5 software (Table 1).
Co-immunoprecipitation
80%~90% confluent HUVECs in 100 mm culture plate
were used for Co-immunoprecipitation (Co-IP) after sti-
mulated with AGE-HSA (50 mg/L for 1 h). Cells were
lysed in the lysis buffer and the lysates were centrifuged
at 10,000 g for 10 min at 4°C. Supernatants were incu-
bated overnight at 4°C with ROCK antibody, moesin
antibody or p-ROCK antibody, respectively, and then
incubated with Protein A/G PLUS-Agarose (Merck,
Darmstadt, Germany) for 3 h at 4
○C. The bead-bound
proteins were eluted with Laemmli’s sample buffer after
washing three times with lysis buffer. The eluted pro-
teins were analyzed by immunoblotting with specific
antibodies.
Endothelial monolayer permeability assay
Endothelial monolayer permeability was measured as
described by Tinsley [31]. ECs were grown to conflu-
ence on 1% gelatin-coated transwell clear polyester
membranes (Corning Costar, Acton, MA, USA), and
were exposed to the indicated reagents before stimula-
tion with AGE-HSA. Then a tracer protein (TRITC-
albumin, 1 g/L) was added to the upper chamber for 45
min, samples were then collected from both the upper
(luminal) and lower (abluminal) chambers for fluorome-
try. The albumin concentration was measured by using
a HTS 7000 microplate reader (Perkin-Elmer, Yoko-
hama, Japan) and a standard curve. The permeability
coefficient for albumin (Pa) was calculated as follows: Pa
= [A]/t·1/A·V/[L], where [A] is the abluminal albumin
concentration, t is the time in seconds, A is the mem-
b r a n ea r e ai nc m
2,Vi st h ev o l u m eo ft h ea b l u m i n a l
chamber, and [L] is the luminal albumin concentration.
F-actin staining
ECs were plated on gelatin-coated glass-bottomed
microwell plates (MatTek, MA, USA) and cultured until
confluence. After appropriate treatment, the cells were
fixed and permeabilized for 15 min at room temperature
in PBS with 3.7% formaldehyde and 0.5% Triton X-100.
After a thorough wash with PBS, cells were incubated
with rhodamine-phalloidin (2,000 U/L) for 40 min at
room temperature. Then the cells were washed three
times with PBS, and the plate was mounted for observa-
tion and imaging with a Leica TCS SP2 laser confocal
scanning microscope (Wetzlar, Germany).
Table 1 Primer sequences and size of Realtime PCR products
Gene Primer Product size (bp)
moesin
surrounding primer
5’ TAAACTTCGCCAACTCCGC 3’ 2114
5’ TCCACACTTGACTCCCATAGG 3’
moesin
clone primer
5’ CTAGAATTCGCGCCCAAAACGATCAGTGTG 3’ 1735
5’ GCGCTCGAGTTACATAGACTCAAATTCGTC 3’
moesin
realtime primer
5’ GATGTGCGGAAGGAAAGC 3’ 158
5’ GTCTCAGGCGGGCAGTAA 3’
GAPDH 5’ GCACCGTCAAGGCTGAGAAC 3’ 138
5’ TGGTGAAGACGCCAGTGGA 3’
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Data were normalized to control values and are reported
as a percentage of the baseline values (mean ± SD) for at
least three independent experiments. Results were ana-
lyzed by one-way ANOVA followed by post hoc compari-
son. The level of significance was set at P < 0.05.
Results
AGE-HSA increase HMVEC monolayer permeability and
stress fiber formation
We have previously reported that AGE-HSA increase the
permeability of monolayers and cause the formation of F-
actin stress fiber in HUVECs [32]. This time, we con-
firmed the effects of AGEs on HMVECs by demonstrating
that incubation with AGE-HSA led to hyperpermeability
of HMVECs in a time- and dose-dependent fashion (Fig-
ure 1A and 1B). The permeability coefficient for albumin
(Pa) was increased to 98.90 ± 10.47% after 8 h of exposure
to AGE-HSA at 50 mg/L (P <0 . 0 1c o m p a r e dw i t ht h e
control) (Figure 2B). AGE-HSA also evoked the appear-
ance of stress fibers in HMVECs (Figure 2A). In contrast,
HSA alone did not cause any alterations of barrier func-
tion or the cytoskeleton in HMVECs.
RhoA activation and ROCK phosphorylation induced by
AGE-HSA
The effect of AGE-HSA on RhoA activity and phosphor-
ylation of ROCK was assessed by a luminescence-based
G-LISA™ assay and immunoblotting. Treatment of
HMVECs with AGE-HSA significantly increased RhoA
activity in a time- and dose-dependent manner. Activa-
tion of RhoA reached its peak after 1 h of exposure at
50 mg/L, with the relative activity being 147.28 ± 7.6%
(P < 0.05 vs. control) (Figure 3A and 3B). Phosphoryla-
tion of ROCK was also enhanced by AGE-HSA in a
time-dependent manner and the highly phosphorylated
state persisted for a long period (Figure 4A and 4B).
Moreover, there was dose dependent phosphorylation of
ROCK as the AGE-HSA concentration increased from
12.5 mg/L to 100 mg/L (Figure 4C and 4D). However,
AGE-HSA showed no effect on ROCK protein expres-
sion, while HSA alone did not enhance activation of
RhoA or phosphorylation of ROCK (Figure 3 and 4).
These findings suggested that AGE-HSA enhanced the
RhoA/ROCK pathway at the post-translational level.
Suppression of RhoA with a dominant negative
adenovirus prevents activation of RhoA and
phosphorylation of ROCK
To further specify the role of RhoA/ROCK pathway in
AGE-HSA-related endothelial changes, RhoA activity
and ROCK phosphorylation were assessed in HMVECs
treated with AGE-HSA at 24 h after infection with
dominant negative RhoA N19 recombinant adenovirus.
Transfection of RhoA N19 down-regulated RhoA activ-
ity in HMVECs, with relative RhoA activity being
decreased from 123.56 ± 2.00% in the AGE-HSA group
with the control vector to 96.86 ± 1.75% in the AGE-
HSA group with RhoA N19 adenovirus (P < 0.05) (Fig-
ure 5A). It was also found that phosphorylation of
ROCK was significantly suppressed by transfection of
RhoA N19 (Figure 5B). Transfection of the constitutively
activated recombinant adenovirus (RhoA L63) mimicked
the effects of AGE-HSA on RhoA and ROCK in cul-
tured HMVECs. Relative activity of RhoA increased by
32.45 ± 2.2% after active RhoA L63 transfection (P <
0.05) (Figure 5A), along with markedly enhanced phos-
phorylation of ROCK (Figure 5B).
Down-regulation of RhoA abolishes AGE-HSA induced
functional and morphological changes in HMVECs
It was indicated that down-regulation of RhoA activity
by transfection of HMVECs with RhoA N19 abolished
the increase of HMVEC monolayer permeability induced
by AGE-HSA treatment (Figure 2B). Formation of F-
actin filament bundles in AGE-HSA-treated cells was
also inhibited by RhoA N19 transfection (Figure 2A),
but RhoA N19 alone did not induce any changes in
HMVECs. Transfection of HMVECs with constitutively
activated RhoA L63 caused an increase of HMVECs
monolayer permeability and disorganization of F-actin
filaments. These findings confirmed the involvement of
RhoA activation in endothelial barrier dysfunction
caused by AGE-HSA.
Inhibition of ROCK activation attenuates the changes of
permeability and F-actin after AGE-HSA stimulation
Our previous study showed that inhibition of ROCK
activation by Y-27632 could suppress the phosphoryla-
tion of moesin induced by AGE-HSA and block the
AGE-evoked increase of HMVEC monolayer permeabil-
ity [20]. H-1152, a more specific and stronger inhibitor
of ROCK [33,34], was used in this study and its admin-
istration abolished both the formation of F-actin stress
fibers and the increase of permeability stimulated by
AGE-HSA (Figure 2).
Down-regulation of RhoA activity attenuates AGE-HSA
induced moesin phosphorylation
To validate the effect of RhoA/ROCK pathway in AGE-
HSA induced moesin phosphorylation, phospho-moesin
was detected in HMVECs transfected with RhoA N19
24 h before AGE-HSA application. RhoA L63 was trans-
fected alone to HMVECs as a positive control. The
results showed that the suppression of RhoA activity by
RhoA N19 obviously attenuated moesin phosphorylation
induced by AGE-HSA (Figure 6A), with relative density
of phospho-moesin decreasing from 1.89 ± 0.165 to
Wang et al. Cardiovascular Diabetology 2012, 11:7
http://www.cardiab.com/content/11/1/7
Page 5 of 18 
A 
50
100
150
200
250
control HSA
124 8 1 2
P
a
 
(
%
 
o
f
 
c
o
n
t
r
o
l
) ** **
**
**
*
᧤᧥ ᧤ ᧥ AGE-HSA᧤ ᧤50 mg/L᧥ ᧤h᧥ ᧥ 
B 
᧤᧥ ᧤ ᧥
50
100
150
200
250
control HSA
12.5 25 50 100
P
a
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
** **
**
*
AGE-HSA᧤8h᧥ ᧤mg/L᧥ 
Figure 1 AGE-HSA induced time-(A) and dose-(B) dependent increases of HMVEC monolayer permeability. HMVECs were treated with 50
mg/L AGE-HSA for 1, 2, 4, 8, or 12 h, or with 12.5, 25, 50, or 100 mg/L AGE-HSA for 8 h. Culture medium was used as the blank control and
HSA was used as the albumin control. Permeability was measured from the transflux of tracer protein TRITC-albumin across monolayers and was
expressed as a coefficient for albumin (Pa). n = 3, *P < 0.05, **P < 0.01 vs control.
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0.05 vs AGE-HSA.
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Figure 3 AGE-HSA induced a time-(A) and dose-(B) dependent increase of RhoA activity. HMVECs were treated with 50 mg/L AGE-HSA for
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activation of RhoA by RhoA L63 could mimicked the
effect of AGE-HSA and significantly enhanced moesin
phosphorylation (Figure 6).
ROCK interacts directly with moesin
To further verify the relationship of ROCK and moesin,
the direct interaction of endogenous ROCK and moesin
after AGE-HSA stimulation was assessed using Immu-
noprecipitation (IP) - Immunoblotting (IB) analysis.
HUVEC extract was obtained after stimulation with 50
mg/L AGE-HSA for 1 h. Physical interaction between
ROCK and moesin was confirmed in HUVECs with or
without AGE-HSA application (Figure 7A, B). The bind-
ing of moesin with phosphor-ROCK was decreased after
AGE-HSA administration (Figure 7C). We speculate
here that the AGE-induced phosphorylation of ROCK
activated moesin and released it to act as the linker pro-
tein, resulting in the redistribution of cytoskeleton.
These data demonstrated that RhoA-ROCK pathway
might work through moesin activation in AGE-HSA
induced endothelial responses.
The inhibiting mutation of moesin attenuates AGE-
induced phosphorylation of moesin
The mutant of moesin was induced by substituting
threonine at 558 amino acid residues with Ala
(pcDNA3/HA-moesin
T558A) as inhibited mutant (Figure
8B), or with Asp (pcDNA3/HA-moesin
T558D)a sa c t i -
vated mutant (Figure 8C), respectively. The eukaryotic
expressions of plasmids of two mutants and pcDNA3/
HA-moesin (Figure 8A) were identified by nucleotide
sequencing. The plasmids transfection efficiency was up
to 30% using Lipofectamine™ LTX and PLUS™
reagents.
The transfection of plasmid pcDNA3/HA-moesin
T558A
into HUVECs decreased the level of phosphorylated
moesin after 1 h of exposure to AGE-HSA at 50 mg/L,
while the transfection of plasmid pcDNA3/HA-moe-
sin
T558D itself could educe phosphorylation of moesin
without AGE-HSA application (Figure 9). The transfec-
tion of control vector pcDNA3/HA and inhibited moe-
sin mutant pcDNA3/HA-moesin
T558A alone into
HUVECs exerted no effect on level of moesin phosphor-
ylation. These results directly indicated that AGE-HSA
caused the phosphorylation of threonine in 558 residues
of moesin.
The inhibiting mutation of moesin attenuates AGE-
induced endothelial hyper-permeability and F-actin
disorganization
Our previous reports have shown that AGE-HSA
increased the monolayer permeability and caused the
formation of F-actin stress fiber in HUVECs and
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Figure 4 AGE-HSA increased phosphorylation of ROCK in a time- and dose-dependent manner. HMVECs were treated with 50 mg/L AGE-
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immunoblotting. Culture medium was used as blank control and HSA was used as albumin control. Results shown are representative IB (A and
B) and densitometry results (C and D). n = 3 independent experiments, *P < 0.05, **P < 0.01 vs control.
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Page 9 of 18HMVECs [15,20]. In this present study, the transfection
of plasmid pcDNA3/HA-moesin
T558A into HUVECs
decreased the hyper-permeability response induced by
AGE-HSA administration (50 mg/L, 1 h) from 158.34 ±
4.17% to 116.67 ± 3.21%. It also preserved the distribu-
tion of F-actin in endothelial cortex area after AGE-
HSA stimulation. The transfection of plasmid pcDNA3/
HA-moesin
T558D itself increased endothelial monolayer
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Figure 5 Effect of transfection of RhoA N19 or RhoA L63 on RhoA activity and ROCK phosphorylation. At 24 h after transfection, HMVECs
were treated with 50 mg/L AGE-HSA for 60 min. RhoA activity and ROCK phosphorylation were assessed with a luminescence-based G-LISA™
assay and immunoblotting, respectively. Culture medium was used as control. *P < 0.05, **P < 0.01 vs control, #P < 0.05 vs AGE-HSA.
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Page 10 of 18permeability to 152.62 ± 7.14%, also triggered the for-
mation of F-actin stress fiber (Figure 10). These results
provide direct evidence for the involvement of phos-
phorylation of moesin in Thr 558 residues in AGE-
induced endothelial dysfunction.
Discussion
It is well known that Rho GTPases play a central role in
the functional regulation of EC barrier function [35].
RhoA/ROCK-dependent modulation of actin cytoskeleton
organization and cell contractility are involved in the regu-
lation of endothelial permeability [18,36,37]. We have pre-
viously demonstrated that ROCK was phosphorylated by
AGE stimulation and that suppression of ROCK activity
by the inhibitor Y-27632 attenuated the AGE-dependent
increase of permeability in ECs [20]. In the present study,
we demonstrated the involvement of the RhoA/ROCK
pathway in cellular responses to AGEs by showing time-
and dose-dependent increases of RhoA activation and
ROCK phosphorylation in HMVECs exposed to AGE-
HSA. Then, using a recombinant adenovirus containing
dominant negative human RhoA (RhoA N19), we showed
that the RhoA activity of transfected HMVECs was signifi-
cantly down-regulated and these cells showed much
weaker responses to AGE-HSA stimulation in terms of
RhoA activation and ROCK phosphorylation compared
with naive HMVECs. Transfection of this virus also atte-
nuated changes of the F-actin cytoskeleton and monolayer
permeability induced by AGE-HSA. On the other hand,
infection with recombinant adenovirus containing
A
Control  AGE-HSA   L63    N19  N19+AGE-HSA 
p-Moesin 
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B B B
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Figure 6 Effect of RhoA N19 on moesin phosphorylation induced by AGE-HSA. RhoA N19 was transfected to HMVECs 24 h before AGE-
HSA (50 mg/L, 60 min) stimulation and moesin phosphorylation was detected by immunoblotting. RhoA L63 was transfected to HMVECs for 24
h as a positive control and phosphor-moesin was assayed. Culture medium was used as blank control. Results shown are representative IB (A)
and densitometry results (B). n = 3 independent experiments. *P < 0.05, vs control, #P < 0.05 vs AGE-HSA.
Wang et al. Cardiovascular Diabetology 2012, 11:7
http://www.cardiab.com/content/11/1/7
Page 11 of 18160KD 
130KD 
90KD 
78KD 
C 
IP  p-ROCK 
IB  ROCK 
IP  p-ROCK 
IB  moesin 
Lysates   Con.Ab  AGE(-)  AGE(+) 
IP  ROCK 
IB  ROCK 
IP  ROCK 
IB  moesin 
B 
160KD 
78KD 
Lysates   Con.Ab  AGE(-)  AGE(+) 
A 
IP  moesin 
IB  ROCK 
IP  moesin 
IB  moesin 
Lysates   Con.Ab  AGE(-)  AGE(+) 
160KD 
78KD 
IgG-H 
IgG-L 
55KD 
25KD 
Figure 7 Physical interaction between ROCK and moesin proteins is confirmed in HUVECs by immunoprecipitation (IP)-
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Page 12 of 18constitutively activated human RhoA (RhoA L63) led to
increased RhoA activation and ROCK phosphorylation, as
well as rearrangement of F-actin in HMVECs and
increased permeability of HMVEC monolayers. H-1152, a
specific ROCK inhibitor, abolished the AGE-induced dis-
arrangement of F-actin and endothelial barrier disruption.
These findings is the first to demonstrate the specific
effects of RhoA activation by actually showing the altera-
tion of RhoA activity and the subsequence of down-regu-
lating RhoA expression in AGE-induced endothelial
dysfunction. These data, together with our previous results
[20], emphasizes the role of the RhoA/ROCK pathway in
AGE-induced endothelial dysfunction.
Hirose et al. have reported that by promoting sponta-
neous formation of the RhoA and RAGE complex,
AGE-BSA induces reorganization of the actin cytoskele-
ton through RAGE/RhoA activation, leading to
increased permeability of HUVECs [14]. Our previous
study also revealed a role of RAGE in AGE-induced
phosphorylation of ROCK [20]. This present study used
HMVECs, which are the cells involved in controlling
vascular barrier function, to verify the influence of
AGEs on vascular endothelial barrier function. Using
dominant negative RhoA N19 and constitutively acti-
vated RhoA L63, this study is the first to specifically
demonstrate the involvement of the RhoA-ROCK path-
way in AGE-related cellular responses.
Various signaling mechanisms, including NAD(P)H
and reactive oxygen species, p38 MAPK, phospholipase
C, and calmodulin-dependent protein kinase
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Figure 8 The nucleotide sequencing of eukaryotic expressions of plasmids. The Thr at 558 amino acid residues of moesin of pcDNA3/HA-
moesin was substituted with Ala or Asp, respectively, to produce inhibited mutant pcDNA3/HA-moesin
T558A or activated mutant pcDNA3/HA-
moesin
T558D. The red circles marks moesin Thr 558 (A), Ala 558 (B), and Asp 558(C), respectively.
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Page 13 of 18[2,20,32,38], have been suggested to have a role in AGE-
induced cellular dysfunction. It would be interesting to
also assess the relation of Rho/ROCK to other pathways
involved in AGE-induced endothelial responses. We
found that inhibition of ROCK with H-1152 attenuated
AGE-HSA-induced phosphorylation of p38 in HMVECs.
Interestingly, inhibition of p38 activation with SB203580
also suppressed the phosphorylation of ROCK (data not
shown). While there is considerable evidence that
RhoA/ROCK regulates p38 MAPK activation [39], p38
might also regulate RhoA/ROCK activity [40], i.e., RhoA
or p38 could be upstream regulators of each other
[39,41,42]. However, more research is needed to clarify
their complicated relation in the responses to AGE-
HSA.
It is necessary to extend the downstream target of
Rho/ROCK since ROCK did not directly interacts with
F-actin. It has been well documented that activation of
RhoA/ROCK can phosphorylate and inactivate myosin
light chain phosphatase (MLCP), hence promoting MLC
phosphorylation and acto-myosin contraction in
endothelial cells [43-47]. Another protein family, ERM
protein family, has also emerged as the possible candi-
date target for ROCK in regulation of endothelial
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Figure 9 Expression of moesin
T558A attenuated AGE-HSA induced phosphorylation of moesin. HUVECs transfected with plasmid pcDNA3/
HA-moesin
T558A were stimulated with 50 mg/L AGE-HSA for 1 h. Plasmid pcDNA3/HA-moesin
T558D was transfected to HUVECs without AGE-HSA
stimulation. The phosphorylation of moesin was detected with immunoblotting. Vector pcDNA3/HA or inhibited moesin mutant pcDNA3/HA-
moesin
T558A alone was also transfected to HUVECs respectively. Results shown are representative IB (A) and densitometry results (B). n = 3
independent experiments. * P < 0.05 and ** P < 0.01 vs control, # P < 0.05 vs AGE-HSA.
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Figure 10 Expression moesin
T558A decreased the hyper-permeability response (A, n = 3) and F-actin redistribution (B) after AGE-HSA
stimulation. HUVECs were stimulated 1 h by 50 mg/L AGE-HSA after transfected with plasmid pcDNA3/HA-moesin
T558A for 24 h, or transfected
with plasmid pcDNA3/HA-moesin
T558D without AGE-HSA stimulation. Representative confocal images of F-actin organization and the formation
of stress fiber in HUVECs were showed with similar results observed in 3 different cultures. * P < 0.05 vs control, # P < 0.05 vs AGE-HSA.
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Page 15 of 18response [21-23]. There are three members, ezrin,
radixin, and moesin in ERM protein family. A new
report has indicated the other members of ERM family,
ezrin and radixin, might also play a role in 2-methoxyes-
tradiol induced modulation of permeability human pul-
monary artery endothelial cells (HPAEC) [48]. But the
expression and phosphorylation of ERM can vary from
endothelium to endothelium and/or from stimuli to sti-
muli. In our previous report [20], we detected the total
ERM protein expression and found out that treatment
with moesin siRNA not only efficiently inhibited the
protein expression of moesin, but also total ERM in
HMVECs. While moesin expression was almost totally
depressed by siRNA, total ERM expression was almost
totally depressed either. This result indicated that in
HMVECs, moesin is the major ERM protein. Function-
ally, down-regulation of moesin expression by siRNA
prevented AGE-induced cytoskeletal changes and per-
meability increases in HMVECs. These results con-
vinced us that moesin is the major ERM in regulation of
endothelial function, especially in HMVECs. Of course,
we could not rule out the involvement of other mem-
bers of ERM family, ezrin and radixin, in regulation of
endothelial function since we did not monitor the phos-
phorylation of ezrin and radixin in this study. Even the
antibody is moesin specific, according to the manufac-
ture datasheet, there is still a possibility that the upper
band in Figure 6 probably indicated ezrin or radixin too,
since the antibody used here can partially detects ezrin
phosphorylated at Thr 567 and radixin phosphorylated
at Thr 564.
Previously, we have demonstrated that the inhibition
of ROCK with Y-27632 attenuated the AGE-induced
phosphorylation of moesin in HMVECs [20]. The data
in this present study indicated again that moesin is the
downstream target of RhoA/ROCK pathway in AGE-
induced endothelial response. The AGE-HSA induced
moesin phosphorylation in Thr558 residue was remark-
ably attenuated by down-regulation of RhoA activation
with dominative negative recombinant adenovirus RhoA
N19. The direct activation of RhoA by constitutively
active recombinant adenovirus RhoA L63 enhanced the
phosphorylation of moesin (Figure 6). This study further
provides a direct evidence to confirm the physical inter-
action of ROCK and moesin by using IP-IB analysis.
Moesin was immunoprecipitated with ROCK in unsti-
mulated cell lysates and AGE stimulation did not alter
the binding of ROCK and moesin (Figure 7A, B). It is
consistent with Hébert et al’s report that ezrin and moe-
sin are immunoprecipitated with ROCK without stimu-
lation in Jurkat cells [49], indicating that ROCK can
bind moesin. However, the binding of phosphor-ROCK
with moesin decreased significantly after AGE applica-
tion (Figure 7C). We speculate here that the activated
ROCK triggered the phosphorylation of moesin and
released moesin from this binding complex to act as
linking protein, resulting in the reorganization of F-
actin.
It has been revealed that tyrosine and threonine resi-
dues are major phosphorylation sites in ERM protein
[23,50,51]. By using specific antibody against phosphor-
Thr moesin, Koss et al. has demonstrated that vascular
permeability increasing mediator, such as TNF-a,c o u l d
phosphorylate threonine 558 of moesin and enhance the
hyper-permeability response in pulmonary microvascular
endothelial cells [52]. In this present study, while the
inhibited mutant plasmid pcDNA3/HA-moesin
T558A was
introduced to HUVECs, the AGE-induced phosphoryla-
tion of moesin was attenuated (Figure 9), as well as the
F-actin disorganization and endothelial barrier dysfunc-
tion (Figure 10). The activated mutant plasmid
pcDNA3/HA-moesin
T558D mimicked the AGE-evoked
endothelial response with formation of F-actin stress
fiber and increase of endothelial monolayer permeability.
These data are consistent with the results from Zhou et
al, indicating that exogenously expressed meosin bears
biochemical characteristics similar to endogenous pro-
tein [53]. Although it is yet to rule out the possibility of
AGE-induced tyrosine phosphorylation since the state of
phosphotyrosine was not detected in this study, the
results have demonstrated that threonine 558 is the
phosphorylation site of moesin in AGE-stimulated
endothelial cells.
Taking together, this study provides direct evidences
to show that the up-regulation of RhoA activity is
involved in AGE-induced endothelial dysfunction.
ROCK physically interacts with moesin and the RhoA-
triggered phosphorylation of ROCK results in phosphor-
ylation of threonine at 558 residue in moesin. This
RhoA/ROCK -dependent moesin phosphorylation regu-
lates AGE-induced endothelial dysfunction.
Abbreviations
AGE: Advanced glycation end products; AGE-HSA: AGE-modified human
serum albumin; DMSO: Dimethylsulfoxide; EC: Endothelial cell; ERM: Ezrin/
radixin/moesin; FBS: Fetal bovine serum; HMVEC: Human dermal
microvascular endothelial cell; HSA: Human serum albumin; HUVECs: Human
umbilical vein endothelial cells; MAPK: Mitogen activated protein kinase; PBS:
Phosphate buffered saline; PCR: Polymerase chain reaction; QPCR: Real-time
quantitative PCR; RAGE: Receptor of AGE; Rho: Ras homologue oncogene;
RNA: ribonucleic acid; ROCK: Rho kinase; RT-PCR: reverse transcription
polymerase chain reaction.
Acknowledgements
This work was supported by General Program from Natural Science
Foundation of China (30771028, 30971201); Grant for Outstanding Creative
Team of Education Department of China (IRT0730); and National Key
Foundation for Basic Science Research of China (G2005CB522601).
Authors’ contributions
QH conceived the study, arranged the collaboration, initiated the
manuscript, edited and compiled the final version for submission. JW and
Wang et al. Cardiovascular Diabetology 2012, 11:7
http://www.cardiab.com/content/11/1/7
Page 16 of 18HL participated in its design and coordination. JW, HL, BCh, QL, XH, LW, XG
performed Laboratory analyses and study design. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 3 December 2011 Accepted: 17 January 2012
Published: 17 January 2012
References
1. Vlassara H, Uribarri J, Cai W, Striker G: Advanced glycation end product
homeostasis: exogenous oxidants and innate defenses. Ann NY Acad Sci
2008, 1126:46-52.
2. Goldin A, Beckman JA, Schmidt AM, Creager MA: Advanced glycation end
products: sparking the development of diabetic vascular injury.
Circulation 2006, 114:597-605.
3. Li R, McCourt P, Schledzewski K, Goerdt S, Moldenhauer G, Liu X,
Smedsrød B, Sørensen KK: Endocytosis of advanced glycation end-
products in bovine choriocapillaris endothelial cells. Microcirculation 2009,
4:1-16.
4. Gao X, Zhang H, Schmidt AM, Zhang C: AGE/RAGE produces endothelial
dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol
Heart Circ Physiol 2008, 295:H491-H498.
5. Peppa M, Uribarri J, Vlassara H: Glucose, advanced glycation end
products, and diabetes complications: what is new and what works.
Clinical Diabetes 2003, 21:186-1873.
6. Rahman S, Rahman T, Ismail AA, Rashid AR: Diabetes-associated
macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes
Metab 2007, 9:767-780.
7. Yamagishi S, Nakamura K, Imaizumi T: Advanced glycation end products
(AGEs) and diabetic vascular complications. Curr Diabetes Rev 2005,
1:93-106.
8. Bu DX, Rai V, Shen X, Rosario R, Lu Y, D’Agati V, Yan SF, Friedman RA,
Nuglozeh E, Schmidt AM: Activation of the ROCK1 branch of the
transforming growth factor-beta pathway contributes to RAGE-
dependent acceleration of atherosclerosis in diabetic ApoE-null mice.
Circ Res 2010, 106:1040-1051.
9. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ: Association
between serum levels of soluble receptor for advanced glycation end
products and circulating advanced glycation end products in type 2
diabetes. Diabetologia 2006, 49:2756-2762.
10. Yoon YW, Kang TS, Lee BK, Chang W, Hwang KC, Rhee JH, Min PK,
Hong BK, Rim SJ, Kwon HM: Pathobiological role of advanced glycation
endproducts via mitogen-activated protein kinase dependent pathway
in the diabetic vasculopathy. Exp Mol Med 2008, 40:398-406.
11. Torreggiani M, Liu H, Wu J, Zheng F, Cai W, Striker G, Vlassara H: Advanced
glycation end product receptor-1 transgenic mice are resistant to
inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J
Pathol 2009, 175:1722-1732.
12. Yuan SY, Breslin JW, Perrin R, Gaudreault N, Guo M, Kargozaran H, Wu MH:
Microvascular permeability in diabetes and insulin resistance.
Microcirculation 2007, 14:363-373.
13. Soro-Paavonen A, Zhang WZ, Venardos K, Coughlan MT, Harris E, Tong DC,
Brasacchio D, Paavonen K, Chin-Dusting J, Cooper ME, Kaye D, Thomas MC,
Forbes JM: Advanced glycation end-products induce vascular
dysfunction via resistance to nitric oxide and suppression of endothelial
nitric oxide synthase. J Hypertens 2010, 28:780-788.
14. Hirose A, Tanikawa T, Mori H, Okada Y, Tanaka Y: Advanced glycation end
products increase endothelial permeability through the RAGE/Rho
signaling pathway. FEBS Lett 2010, 584:61-66.
15. Wang Zh, Guo X, Liu X, Wang J, Wang L, Huang Q: The morphological
changes of vascular endothelial cadherin in human umbilical vein
endothelial cells induced by advanced glycation end products. Chin J
Arterioscler 2008, 16:505-509.
16. Birukova AA, Smurova K, Birukov KG, Usatyuk P, Liu F, Kaibuchi K, Ricks-
Cord A, Natarajan V, Alieva I, Garcia JG, Verin AD: Microtubule disassembly
induces cytoskeletal remodeling and lung vascular barrier dysfunction:
role of Rho-dependent mechanisms. J Cell Physiol 2004, 201:55-70.
17. Gorovoy M, Niu J, Bernard O, Profirovic J, Minshall R, Neamu R, Voyno-
Yasenetskaya T: LIM kinase 1 coordinates microtubule stability and actin
polymerization in human endothelial cells. J Biol Chem 2005,
280:26533-26542.
18. Van Nieuw Amerongen GP, Beckers CM, Achekar ID, Zeeman S, Musters RJ,
van Hinsbergh VW: Involvement of Rho kinase in endothelial barrier
maintenance. Arterioscler Thromb Vasc Biol 2007, 27:2332-2339.
19. Van Nieuw Amerongen GP, Musters RJ, Eringa EC, Sipkema P, van
Hinsbergh VW: Thrombin-induced endothelial barrier disruption in intact
microvessels: role of RhoA/Rho kinase-myosin phosphatase axis. Am J
Physiol Cell Physiol 2008, 294:C1234-C1241.
20. Guo X, Wang L, Chen B, Li Q, Wang J, Zhao M, Wu W, Zhu P, Huang X,
Huang Q: ERM protein Moesin is phosphorylated by advanced glycation
end products and modulate vascular permeability. Am J Physiol Heart Circ
Physiol 2009, 297:H238-H246.
21. Mangeat P, Roy C, Martin M: ERM proteins in cell adhesion and
membrane dynamics. Trends Cell Biol 1999, 9:187-192.
22. Niggli V, Rossy JR: Ezrin/radixin/moesin: versatile controllers of signaling
molecules and of the cortical skeleton. Int J Biochem Cell Biol 2008,
40:344-349.
23. Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S,
Tsukita S: Rho-kinase phosphorylates COOH-terminal threonines of ezrin/
radixin/moesin (ERM) proteins and regulates their head-to-tail
association. J Cell Biol 1998, 140:647-657.
24. Berryman M, Franck Z, Bretscher A: Ezrin is concentrated in the apical
microvilli of a wide variety of epithelial cells whereas moesin is found
primarily in endothelial cells. J Cell Sci 1993, 105:1025-1043.
25. Li Q, Liu H, Du J, Chen B, Li Q, Guo X, Huang X, Huang Q: Advanced
glycation end products induce moesin phosphorylation in murine brain
endothelium. Brain Res 2011, 1373:1-10.
26. Hou FF, Boyce J, Chertow GM, Kay J, Owen WF Jr: Aminoguanidine
inhibits advanced glycation end products formation on beta2-
microglobulin. J Am Soc Nephrol 1998, 9:277-283.
27. Hou FF, Miyata T, Boyce J, Yuan Q, Chertow GM, Kay J, Schmidt AM,
Owen WF: Beta(2)-Microglobulin modified with advanced glycation end
products delays monocyte apoptosis. Kidney Int 2001, 59:990-1002.
28. Stein GH, St Clair JA: Human microvascular endothelial cells: coordinate
induction of morphologic differentiation and twofold extension of life
span. In Vitro Cell Dev Bio 1998, 24:381-387.
29. Takagi M, Nishioka M, Kakihara H, Kitabayashi M, Inoue H, Kawakami B,
Oka M, Imanaka T: Characterization of DNA polymerase from Pyrococcus
sp. strain KOD1 and its application to PCR. Appl Environ Microbio 1997,
63:4504-4510.
30. Hashimoto H, Nishioka M, Fujiwara S, Takagi M, Imanaka T, Inoue T, Kai Y:
Crystal structure of DNA polymerase from hyperthermophilic archaeon
Pyrococcus kodakaraensis KOD1. J Mol Biol 2001, 306:469-77.
31. Tinsley JH, Wu MH, Ma W, Taulman AC, Yuan SY: Activated neutrophils
induce hyperpermeability and phosphorylation of adherens junction
proteins in coronary venular endothelial cells. J Biol Chem 1999,
274:24930-24934.
32. Guo X, Huang Q, Chen B, Wang S, Hou F, Fu N: Mechanism of advanced
glycation end products-induced hyperpermeability in endothelial cells.
Acta Physiol Sino 2005, 57:205-210.
33. Breitenlechner C, Gassel M, Hidaka H, Kinzel V, Huber R, Engh RA,
Bossemeyer D: Protein kinase A in complex with Rho-kinase inhibitors Y-
27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 2003,
1:1595-1607.
34. Sasaki Y, Suzuki M, Hidaka H: The novel and specific Rho-kinase inhibitor
(S)-(+)-2-methyl-1-[(4-methyl- 5-isoquinoline)sulfonyl]-homopiperazine as
a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther
2002, 93:225-232.
35. Shimada H, Rajagopalan LE: Rho kinase-2 activation in human endothelial
cells drives lysophosphatidic acid-mediated expression of cell adhesion
molecules via NF-kappaB p65. J Biol Chem 2010, 285:12536-12542.
36. Komarova Y, Malik AB: Regulation of endothelial permeability via
paracellular and transcellular transport pathways. Annu Rev Physiol 2010,
72:463-493.
37. Sun H, Breslin JW, Zhu J, Yuan SY, Wu MH: Rho and ROCK signaling in
VEGF-induced microvascular endothelial hyperpermeability.
Microcirculation 2006, 13:237-47.
38. You J, Peng W, Lin X, Huang QL, Lin JY: PLC/CAMK IV-NF-kappaB involved
in the receptor for advanced glycation end products mediated signaling
Wang et al. Cardiovascular Diabetology 2012, 11:7
http://www.cardiab.com/content/11/1/7
Page 17 of 18pathway in human endothelial cells. Mol Cell Endocrinol 2010,
320:111-117.
39. Bogatcheva NV, Adyshev D, Mambetsariev B, Moldobaeva N, Verin AD:
Involvement of microtubules, p38, and Rho kinases pathway in 2-
methoxyestradiol-induced lung vascular barrier dysfunction. Am J Physiol
Lung Cell Mol Physiol 2007, 292:487-499.
40. Garcia MC, Ray DM, Lackford B, Rubino M, Olden K, Roberts JD: Arachidonic
acid stimulates cell adhesion through a novel p38 MAPK-RhoA signaling
pathway that involves heat shock protein 27. J Biol Chem 2009,
284:20936-20945.
41. Kamaraju AK, Roberts AB: Role of Rho/ROCK and p38 MAP kinase
pathways in transforming growth factor-beta-mediated Smad-
dependent growth inhibition of human breast carcinoma cells in vivo. J
Biol Chem 2005, 280:1024-1036.
42. Marinissen MJ, Chiariello M, Gutkind JS: Regulation of gene expression by
the small GTPase Rho through the ERK6 (p38 gamma) MAP kinase
pathway. Genes 2001, 15:535-553.
43. Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y,
Matsumura F: Distinct roles of ROCK (Rho-kinase) and MLCK in spatial
regulation of MLC phosphorylation for assembly of stress fibers and
focal adhesions in 3T3 fibroblasts. J Cell Biol 2000, 150:797-806.
44. Essler M, Amano M, Kruse HJ, Kaibuchi K, Weber PC, Aepfelbacher M:
Thrombin inactivates myosin light chain phosphatase via Rho and its
target Rho kinase in human endothelial cells. J Biol Chem 1998,
273:21867-21874.
45. Essler M, Retzer M, Bauer M, Heemskerk JW, Aepfelbacher M, Siess W: Mildly
oxidized low density lipoprotein induces contraction of human
endothelial cells through activation of Rho/Rho kinase and inhibition of
myosin light chain phosphatase. J Biol Chem 1999, 274:30361-30364.
46. Shen Q, Wu MH, Yuan SY: Endothelial contractile cytoskeleton and
microvascular permeability. Cell Health Cytoskelet 2009, 1:43-50.
47. Prasain N, Stevens T: The actin cytoskeleton in endothelial cell
phenotypes. Microvasc Res 2009, 77:53-63.
48. Bogatcheva NV, Zemskova MA, Gorshkov BA, Kim KM, Daglis GA, Poirier C,
Verin AD: ERM are Phosphorylated in Response to 2-methoxyestradiol
and Modulate Endothelial Hyperpermeability. Am J Respir Cell Mol Biol
2011.
49. Hébert M, Potin S, Sebbagh M, Bertoglio J, Bréard J, Hamelin J: Rho-ROCK-
dependent ezrin-radixin-moesin phosphorylation regulates Fas-mediated
apoptosis in Jurkat cells. J Immunol 2008, 181:5963-5973.
50. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR:
LRRK2 phosphorylates moesin at threonine-558: characterization of how
Parkinson’s disease mutants affect kinase activity. Biochem J 2007,
405:307-317.
51. Coffey GP, Rajapaksa R, Liu R, Sharpe O, Kuo CC, Krauss SW, Sagi Y,
Davis RE, Staudt LM, Sharman JP, Robinson WH, Levy S: Engagement of
CD81 induces ezrin tyrosine phosphorylation and its cellular
redistribution with filamentous actin. J Cell Sci 2009, 122:3137-3144.
52. Koss M, Pfeiffer GR, Wang Y, Thomas ST, Yerukhimovich M, Gaarde WA,
Doerschuk CM, Wang Q: Ezrin/radixin/moesin proteins are
phosphorylated by TNF-alpha and modulate permeability increases in
human pulmonary microvascular endothelial cells. J Immunol 2006,
176:1218-1227.
53. Zhou R, Cao X, Watson C, Miao Y, Guo Z, Forte JG, Yao X: Characterization
of protein kinase A-mediated phosphorylation of ezrin in gastric parietal
cell activation. J Biol Chem 2003, 37:35651-35659.
doi:10.1186/1475-2840-11-7
Cite this article as: Wang et al.: RhoA/ROCK-dependent moesin
phosphorylation regulates AGE-induced endothelial cellular response.
Cardiovascular Diabetology 2012 11:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wang et al. Cardiovascular Diabetology 2012, 11:7
http://www.cardiab.com/content/11/1/7
Page 18 of 18